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Lymphangioleiomyomatosis is an uncommon progressive disease characterized by hamartomatous smooth muscle
proliferation of the airways within the lungs as well as the lymph nodes, lymphatics, and blood vessels of the lungs,
mediastinum, and abdomen. The most common manifestations of lymphangioleiomyomatosis are pulmonary
symptoms. Primary abdominal lymphangioleiomyomatosis without any pathological changes in the respiratory system is
extremely unusual. We report a case of primary abdominal lymphangioleiomyomatosis located between the left hepatic
and gastric antrum of a 29-year-old woman. The patient had no typical symptoms of lymphangioleiomyomatosis
(dyspnea, pneumothorax) or abdominal pain. All physical examination findings were normal. Laboratory test results,
including routine blood examination, liver and kidney function, tumor markers, blood coagulation function, and urine
and stool examinations, were all normal. She found abdominal cyst in an annual medical examination by ultrasonography
and confirmed by computed tomography. For a clear diagnosis, a laparoscopic abdominal mass resection was performed.
The postoperative pathohistological examination findings allowed for the definitive diagnosis. This case report may
advance the understanding of primary peritoneal lymphatic leiomyoma and reduce the number of mistakenly
diagnosed patients.
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Lymphangioleiomyomatosis (LAM) was first reported
50 years ago; however, only about 100 cases have been
published since then [1]. LAM is characterized by the pro-
liferation of abnormal smooth muscle cells (LAM cells),
which leads to the development of cystic lung lesions and
lymphatic abnormalities [2]. Almost all cases of LAM in
women occur during the reproductive period [3]. Micro-
scopically, LAM is characterized by diffuse proliferation of
smooth muscle cells (LAM cells) arranged in fascicular,
trabecular, and papillary patterns associated with slit-like
vascular channels. Immunohistochemical studies have
shown strong reactivity of most LAM cells to α-smooth
muscle actin and smooth muscle myosin heavy chain and* Correspondence: shusenzheng@zju.edu.cn
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unless otherwise stated.weak to moderate reactivity of fewer cells to desmin and
nonmuscle myosin heavy chain II-B [4].
According to previous reports, the initial symptoms and
radiographic changes in patients with LAM are always as-
sociated with the respiratory system [5]. The most com-
mon manifestations of LAM are pulmonary symptoms
including progressive dyspnea, recurrent pneumothoraces,
and chylous effusions [6]. Computed tomography (CT)
scans, the findings of which are almost pathognomonic,
show numerous thin-walled cysts throughout the lungs [7].
Although it is reported this disease almost primarily
affects the lungs, severe cases of extrapulmonary LAM
have also been reported. As Matsui et al. described,
many of patients with extrapulmonary LAM would de-
velop pulmonary LAM within 1 to 2 years after diagno-
sis [3]. Common extrapulmonary presentations include
retroperitoneal adenopathy (77%) and renal angiomyoli-
pomas (60%), which can always be identified by CT
scans as the disease progresses [7,8]. To the best of our
knowledge, only four case reports of patients with LAM
who presented with abdominal pain as the first symptomhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the respiratory system were found in all of these patients
after further examination [8]. The diagnosis of LAM
almost completely depends on progressive respiratory
symptoms and typical pulmonary imaging findings [9].
In summary, primary abdominal LAM (PA-LAM) is ex-
tremely difficult to diagnose because it shows no typical
respiratory system symptoms or imaging changes [10].
LAM is considered to be an invasive disease, and a delay
in the diagnosis may lead to a poor prognosis [11,12].
Therefore, we believe that patients with PA-LAM may
benefit from early diagnosis, particularly by postoperative
pathological examination, and intervention, including sur-
gical resection. When a diagnosis of LAM is temporarily
impossible, timely surgical treatment may be helpful for
an early diagnosis, thereby improving the prognosis.
We herein describe a patient with PA-LAM with no re-
spiratory or abdominal symptoms and an absence of any
pulmonary imaging findings during a 6-month follow-up
period. The diagnosis of PA-LAM was not made until a
pathohistological examination was performed after surgi-
cal resection.
Case presentation
A 27-year-old asymptomatic woman was admitted to the
hospital because of an abdominal mass that had beenFigure 1 Image findings. Abdominal ultrasonography (US) showed a righ
lymphatic cyst was considered (A). An abdominal contrast-enhanced CT sc
10.47 × 66.10 cm in size (B). The density of the cyst was homogeneous, an
significant abnormalities before the operation (D).detected during a routine examination. She denied having
any respiratory symptoms, including cough, expectoration,
asthma, fever, or dyspnea on exertion. Additionally, she
had no history of abdominal pain, early satiety, flatulence,
gastrointestinal bleeding, or vomiting throughout the last
year. All physical examination findings were normal. La-
boratory test results, including routine blood examination,
liver and kidney function, tumor markers, blood coagula-
tion function, and urine and stool examinations, were all
normal.
Abdominal ultrasonography (US) showed a right ab-
dominal cystic mass with segmentation, and the pres-
ence of a lymphatic cyst was considered (Figure 1A). An
abdominal contrast-enhanced CT scan revealed a large
cyst between the liver and stomach, approximately
10.47 × 6.61 cm in size (Figure 1B). The density of the
cyst was homogeneous, and no obvious contrast signal
was noted (Figure 1C).
A chest X-ray showed no significant abnormalities be-
fore the operation (Figure 1D). A laparoscopic abdom-
inal mass resection was performed to establish the
patient’s diagnosis. At the time of the operation, a cystic
mass about 10 cm in diameter was found near the hepa-
torenal ligament in the right abdomen. No metastatic le-
sions were detected in other organs. The cyst was
gradually freed and completely resected. The duration oft abdominal cystic mass with segmentation, and the presence of a
an revealed a large cyst between the liver and stomach, approximately
d no obvious contrast signal was noted (C). Chest X-ray showed no
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was about 10 mL. On gross evaluation, the mass was filled
with clear cystic fluid containing a small amount of a jelly-
like substance. The final pathological examination showed
that the cyst comprised various lymph vessels, and smooth
muscle cells were observed in part of the capsule wall
(Figure 2A). Immunohistochemical studies showed strong
reactivity of most cells for D2-40 and CD34 and weak to
moderate reactivity of fewer cells to smooth muscle actin
and F8-R-Ag (Figure 2B).
In summary, the pathological findings indicated the
presence of PA-LAM. According to previous reports,
pulmonary LAM was found in almost all cases of extra-
pulmonary LAM during subsequent treatments. How-
ever, neither the preoperative chest X-ray nor the
postoperative lung CT scan suggested the presence of
pulmonary LAM.
No adjuvant therapy, such as chemotherapy, was ad-
ministered after the surgery. The patient recovered well
and has had no evidence of recurrence. No pulmonaryFigure 2 H&E and immunohistochemical studies. H&E showed the mas
jelly-like substance. The final pathological examination showed that the cys
observed in part of the capsule wall ((A) × 100 field, (B) × 400 field). Immun
(C) and CD34 (D) and weak to moderate reactivity of fewer cells to smoothor abdominal abnormalities were found by CT scan
(Figure 3A,B) during the 1-year follow-up.
Discussion
LAM, a rare progressive disease of unknown etiology, is
almost exclusively seen in women, normally in their repro-
ductive years and at an average age of 41 years at diagno-
sis. The clinical presentation of LAM was first reported by
Stossel in 1937. The typical pathological characteristics of
LAM are hamartomatous proliferation of immature
smooth muscle cells within the lymph nodes, lymphatics,
blood vessels, and small airways. LAM primarily affects
the lungs and mediastinum. Proliferation of LAM cells
could result in the obstruction of the lymphatics, vessels,
and airways, leading to the appearance of classic clinical
symptoms such as chylous effusion, progressive dyspnea,
recurrent pneumothorax, and hemoptysis. Jonson and
Urban reported that the estimated prevalence of LAM is
around 1 per 1 million women in the United Kingdom,
France, and the United States [13,14]. While in Asia,s was filled with clear cystic fluid containing a small amount of a
t comprised various lymph vessels, and smooth muscle cells were
ohistochemistry showed strong reactivity of most cells for D2-40
muscle actin (E) and F8-R-Ag (F).
Figure 3 Lung imaging and follow-up examination. Lung CT scan (A) and abdominal ultrasonography (B) showed no obvious abnormality
during the 1-year follow-up.
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ported an incidence of 2.6 per 1 million women without
evidence of genetic disease [15].
The precise pathogenesis of LAM is unclear. One hy-
pothesis states that smooth muscle proliferation is likely
to be stimulated by steroidal hormones because the on-
set of LAM predominately occurs in premenopausal
women, and exacerbation of LAM occurs during preg-
nancy or administration of estrogen [16]. Genetic studies
have demonstrated that sporadic LAM is strongly re-
lated to a mutation of one of the tuberous sclerosis com-
plex genes on chromosome 16 [17]. However, the exact
mechanism of LAM remains to be elucidated.
Historically, the prognosis of LAM was poor, with a me-
dian survival of 8 to 10 years [14,18]. With progress in sur-
gery and medical technology, however, the 10-year survival
rate is now about 78% to 91% [18,19]. Immunohistochemi-
cally, LAM cells usually express a representative smooth
muscle phenotype and are consistently positive for HMB-
45, a monoclonal melanoma-associated marker that reacts
with a premelanosome-associated glycoprotein [20]. These
cells can also be immunoreactive for estrogen and/or pro-
gesterone receptors [21].
However, more unusual cases have also been reported.
A few cases of LAM have developed in postmenopausal
women [19,22]. Many of these women were receiving or
had received hormone replacement therapy. Several
cases of LAM have even been reported in men since
1996 [23]. The retroperitoneum, mesentery, inguinal and
supraclavicular lymph nodes, and ureters may also be
sporadically involved. With respect to extrapulmonary
locations, lymphadenopathy may be detected in the ab-
domen or pelvis, or chylous ascites, renal angiomyolipo-
mas [24], uterine fibroid [25], or lymphaticoureteric and
lymphaticovenous communications may develop [26,27].
Most cases of extrapulmonary LAM are accompanied by
pulmonary involvement. Extrapulmonary LAM, espe-
cially retroperitoneal LAM, without lung involvementhas rarely been reported. Kebria identified 9 cases of
retroperitoneal LAM among 21 cases of extrapulmonary
LAM, and Tanaka reported one case of retroperitoneal
LAM in Japan. Almost all manifestations in these pa-
tients were acute abdominal pain or abdominal masses.
To the best of our knowledge, the patient described in
the present report is the first clinically asymptomatic pa-
tient to receive a diagnosis of primary retroperitoneal
LAM without pulmonary involvement. Immunohisto-
chemical studies confirmed that the LAM cells in this
case were reactive to smooth muscle actin, F8-R-Ag, D2-
40, and CD34; contrary to other cases, these LAM cells
were negative for HMB-45 expression. This case repre-
sents a unique exception to the typical course of LAM
and will help physicians to have a better understanding
of LAM.
Because the etiology of LAM remains unknown, no
standard effective treatment has been established. Multiple
treatments have been applied with various effects. Treat-
ment of pulmonary LAM is based on hormonal manipu-
lations with intramuscular or oral medroxyprogesterone
to prevent progressive lung destruction [28], and lung
transplantation may be performed in advanced cases
[26,29-31]. Moreover, thoracostomy or chemical pleurod-
esis is recommended for chylous effusion. The treatment
of extrapulmonary LAM is not well defined. Paracentesis
or peritoneovenous shunting is recommended for patients
with chylous ascites. Hormonal manipulation, such as
treatment with progesterone, oophorectomy, tamoxifen,
or gonadotropin-releasing hormone agonists, has demon-
strated mixed responses [32]. However, when managing
retroperitoneal LAM involving no other sites, surgical re-
section is the most commonly used strategy and the only
therapeutic option because of the uncertain behavior of
this entity.
The diagnosis of LAM can be a dilemma because of
the rarity of this disease, the lack of diagnostic suspicion
in most cases, and the need to distinguish malignant
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as cysts. Such a diagnostic dilemma occasionally results
in a delayed or missed diagnosis. Matsui et al. stated
that many patients with extrapulmonary LAM develop
pulmonary LAM within 1 to 2 years after the initial
diagnosis [3].
Based on the present report and a review of the litera-
ture, LAM may originate from the retroperitoneum with
no clinical symptoms and form a huge abdominal mass,
as in the present case. LAM should be considered as a
differential diagnosis of an abdominal space-occupying
lesion, particularly in women of reproductive age, pa-
tients with tuberous sclerosis complex, or postmeno-
pausal women who have undergone or are undergoing
hormonal replacement therapy. The performance of
high-resolution CT of the chest, abdomen, and pelvis in
patients suspected to have LAM is strongly suggested
because these imaging studies are noninvasive, sensitive,
specific, and able to prevent a delayed or missed diagno-
sis and unnecessary surgical biopsy. Surgical resection is
the first option to consider in patients with extrapul-
monary LAM. Additionally, any patient diagnosed with
retroperitoneal LAM must be studied and followed up
with high-resolution chest CT to achieve an early diag-
nosis of possible pulmonary involvement, which will fa-
cilitate treatment in the early stages of the disease and
improve the prognosis.
Further reports of LAM, clinical trials, and research
will hopefully provide a better understanding of the eti-
ology, diagnosis, and treatment options for patients af-
fected by LAM.
Conclusions
We herein describe a patient with PA-LAM with no re-
spiratory or abdominal symptoms and an absence of any
pulmonary imaging finding during a 6-month follow-up
period. The diagnosis of PA-LAM was not made until a
pathohistological examination was performed after sur-
gical resection. This case showed that when a diagnosis
of LAM is temporarily impossible, timely surgical treat-
ment may be helpful for an early diagnosis, thereby im-
proving the prognosis.
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